Twelve years after MERS emerged, 88% of the human research comes from one country

A scoping review of published human research on MERS-CoV across the Gulf Cooperation Council countries identified 171 peer-reviewed studies — 88.3% of them from Saudi Arabia [s1].

That concentration is the review's central finding, and it describes a structural weakness in the evidence base for a coronavirus that continues to circulate in the region and that the review characterises as a substantial ongoing public health challenge [s1].

What the review counted

The authors examined the geographic distribution, methodological characteristics and thematic priorities of the published literature, with the explicit aim of identifying evidence gaps rather than synthesising findings [s1]. It is a map of what has been studied, not a summary of what is known.

Research output peaked in 2016 and again in 2019, then declined in a period coinciding with the COVID-19 pandemic [s1]. The timing is worth sitting with. A global respiratory pandemic drew research attention, funding and laboratory capacity toward SARS-CoV-2 — including in the countries where MERS-CoV surveillance matters most — and MERS output fell during precisely the years when coronavirus research capacity worldwide was expanding fastest.

The methodological picture

Cross-sectional designs were the most common approach at 43.3%, and 95.3% of studies relied on non-probability sampling [s1].

That second figure is the one that constrains what the literature can support. Non-probability sampling means participants were not selected in a way that allows results to be generalised to a defined population — convenience samples, hospital case series, whoever was available. For descriptive and clinical purposes that is often adequate. For estimating how common infection is in a population, or how many mild cases go undetected for every severe one identified, it is not.

Epidemiology and surveillance was the leading thematic focus at roughly 24%, and case fatality rate was the most frequently reported metric, appearing in 43.9% of studies [s1].

Case fatality rate is a number that depends almost entirely on the denominator. If a surveillance system finds severe hospitalised cases and misses mild ones, the calculated fatality rate will be high — not because the virus is more lethal, but because the mild cases are invisible. A literature that reports case fatality rate more often than any other metric, while relying overwhelmingly on non-probability sampling, is a literature in which that number carries substantial uncertainty.

The genomic gap

The review identified limited genomic investigations, with Clade B representing 71.4% of characterised strains [s1].

Clade assignment is how a virus's evolution gets tracked — which lineages are circulating, whether new ones are emerging, whether transmissibility or severity is changing. Answering questions of that kind requires continuous genomic sequencing of human cases, and the review's finding is that such investigations across the GCC have been limited, with Clade B accounting for 71.4% of what has been characterised [s1].

That is a different kind of gap from the sampling problem. Non-probability sampling limits inference from existing data; sparse genomics means the data for a specific and consequential question is not being generated.

Why single-country concentration is a problem

Saudi dominance of the literature may partly reflect where reported cases have concentrated. But an evidence base concentrated in one country inherits that country's surveillance architecture, case definitions, healthcare-seeking patterns and reporting practices — and cannot easily distinguish genuine epidemiological differences between GCC states from differences in how each detects and reports.

The review's own conclusion is framed in exactly these terms: geographic concentration, methodological heterogeneity and thematic limitations, with a need for expanded research scope and enhanced regional collaboration [s1].

What a scoping review can and cannot establish

A scoping review characterises a literature; it does not assess the quality of individual studies or pool their results. So this paper does not show that MERS-CoV epidemiology is misunderstood — only that the published research has particular shape and particular blind spots.

It also covers published, peer-reviewed human studies. National surveillance data, ministry reports, and unpublished genomic sequencing may exist outside that frame. A gap in the literature is not automatically a gap in what health authorities know, though in practice the two tend to correlate.

What to watch next

Whether genomic surveillance output recovers to its pre-2020 level. The COVID-19 response left the Gulf states with substantially expanded sequencing infrastructure — the laboratories, the trained personnel, the bioinformatics pipelines. Whether that capacity gets pointed at the coronavirus that has been circulating in the region since 2012 is a concrete, observable test of whether pandemic preparedness investment persists once the pandemic that funded it recedes.

Sources

1. Human Middle East Respiratory Syndrome Coronavirus (MERS-CoV) research in the Gulf Cooperation Council Countries: A mapping scoping review of epidemiology, clade, and research priority gaps — Journal of Infection and Public Health, 28 May 2026 (primary)